Cardiovascular Disease News
-
Creative Proteomics Unleashes the Exosome Untargeted Metabolomics Service
Creative Proteomics, the globally recognized proteomics, metabolomics, and multi-omics service provider, is delighted to introduce its exosome untargeted metabolomics services—a premier-stage offering in their broad catalogue services. Exosomes are tiny extracellular vesicles, hosting a diverse array of molecules including proteins, RNAs, and metabolites. With a diameter ranging between ...
-
Creative Enzymes Introduces S-Adenosyl-L-Homocysteine Hydrolase, Recombinant
Creative Enzymes, a global leader in enzyme production, is thrilled to announce the latest addition to their hydrolase product line, the Recombinant S-Adenosyl-L-Homocysteine Hydrolase (SAHH). This announcement underscores its unwavering commitment to enzyme innovation and proven track to offering scientifically advanced products. SAHH, a crucial enzyme involved in the biological methylation ...
-
Cutting-edge Homocysteine Methyltransferase, Recombinant for Enhanced Bioprocessing
Creative Enzymes, a leading global supplier and manufacturer of quality enzymes, is thrilled to introduce the availability of Recombinant Homocysteine Methyltransferase, dedicated to assisting researchers and industrial clients to unravel the complexity of enzyme activity. Originated from Pichia pastoris, the Homocysteine Methyltransferase, Recombinant has raised the bar in the field of ...
-
Expanding Possibilities: CD Formulation Unveils Comprehensive Selection of 90+ Active Pharmaceutical Ingredients
Emerging as an excipient supplier and a contract research organization (CRO), CD Formulation has flourished in the pharmaceutical industry. The company recently unveiled its latest collection of over 90 active pharmaceutical ingredients (APIs) to the scientific community. These APIs will serve as essential components in the formulation of various drugs. APIs are the primary components of ...
-
Bayer to start Phase III study with finerenone in adults with chronic kidney disease and type 1 diabetes
Phase III study FINE-ONE will evaluate the efficacy and safety of finerenone versus placebo in delaying the progression of chronic kidney disease (CKD) in adults with CKD and type 1 diabetes (T1D) CKD affects up to 40% of people with T1D A quarter of people with CKD associated with T1D progress to end-stage kidney disease Only limited treatment options are available for people with CKD and ...
By Bayer AG
-
Daxor Corporation Announces Significant Expansion With Five Hospitals Implementing Its BVA-100 Blood Volume Diagnostic for Heart Failure Patients
Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces five new hospitals have implemented the Company’s BVA-100 blood volume diagnostic for clinical use to guide fluid management in heart failure patients during the first quarter of 2023. The addition of these hospitals contributes to the significant growth of blood volume analysis (BVA) ...
-
BIO Investor Forum Company Snapshot: InvivoSciences
BIO Investor Forum Company Snapshot: InvivoSciences What is your company’s lead product or technology? InvivoSciences, Inc. (IVS) is a leading developer of proprietary human 3D cell/tissue culture models for highly-predictive, multi-parameter phenotypic assays both in pharmacology safety & discovery screening and in personalized and regenerative medicine. IVS’s Functional 3D ...
-
Bayer completes acquisition of Blackford Analysis Ltd.
Closing follows announcement of acquisition on January 18, 2023 Acquisition bolsters Bayer’s position in digital medical imaging Blackford will utilize Bayer’s well established “arm’s length” operating model to preserve the company’s entrepreneurial culture Bayer today announced that the company has completed the acquisition of the global strategic ...
By Bayer AG
-
Kerendia (finerenone) granted expanded indication in the EU for broad range of patients with chronic kidney disease and type 2 diabetes
European Commission granted approval for a label update to extend the indication of Kerendia™ to early stages of chronic kidney disease (CKD) associated with type 2 diabetes (T2D) and to include findings from the Phase III FIGARO-DKD cardiovascular (CV) outcomes study FIGARO-DKD included approximately 7,400 patients across a broad range of disease severity, including stages 1-4 CKD ...
By Bayer AG
-
Bayer acquires Blackford Analysis Ltd. bolstering the company’s position in digital medical imaging
Acquisition is part of Bayer’s innovation strategy in radiology Blackford Analysis provides cutting-edge radiology AI (artificial intelligence) platform technology Following closing of the acquisition, Blackford Analysis to become part of Bayer’s well established “arm’s length” operating model to preserve the company’s entrepreneurial culture Bayer today ...
By Bayer AG
-
AskBio Announces Strategic Collaboration with ReCode Therapeutics to Explore Single Vector Gene Editing Platform
Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, announced today that it has signed a multi-year research collaboration and option agreement with ReCode Therapeutics. Under this agreement, the companies will work together to potentially discover precision genetic medicines through the development of a novel platform for full gene ...
By Bayer AG
-
Finerenone receives positive CHMP opinion for EU-label extension for broad range of patients with chronic kidney disease and type 2 diabetes
CHMP opinion is based on the results from the Phase III FIGARO-DKD cardiovascular (CV) outcomes study in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), which included approximately 7,400 patients across a broad range of disease severity, including stages 1-4 CKD associated with T2D The positive data from FIGARO-DKD demonstrated that finerenone significantly reduced the ...
By Bayer AG
-
XyloCor Therapeutics Commences Phase 2 Component of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina
Independent Data Monitoring Committee authorized proceeding to Phase 2 at highest dose level tested following review of clinical safety data from the Phase 1 dose escalation Phase 2 clinical data readouts on safety and efficacy of XC001 anticipated in 2022 Company plans to commence study startup of XC001 as an adjunct to CABG in 2H21, and clinical studies in additional cardiovascular ...
-
Structure-Based Search for Novel Antihypercholestrolemic Agents
DESCRIPTION (provided by applicant): Heart disease is the leading cause of death for both men and women in the US, accounting for nearly 40% of all annual deaths. A high cholesterol level is a well-known risk factors for heart disease. Although blood cholesterol can be lowered using a number of marketed drugs, of which statins are the leading drugs, only 38% of patients taking these drugs are ...
-
Novel Modulators of LDL Metabolism
DESCRIPTION provided by applicant Heart disease is the leading cause of death for both men and women in the US accounting for nearly of all annual deaths A high cholesterol level is well known risk factors for heart disease Although blood cholesterol can be lowered using a number of marketed drugs of which statins are the leading drugs only of patients taking these drugs are achieving the low ...
-
Elucid’s Next-Generation Plaque Analysis and FFRCT Technology to be Featured on 2022 AHA Scientific Sessions Program
BOSTON – November 4, 2022 – Elucid, Inc., a medical technology company providing physicians AI-powered imaging analysis software to characterize cardiovascular disease, has announced that the company’s technology will be featured on the program at the 2022 American Heart Association (AHA) Scientific Sessions, November 5-7, 2022 in Chicago. Elucid has developed FDA-cleared ...
By Elucid
-
Elucid Appoints Dr. Michael Lesh to Board of Directors
BOSTON, November 3, 2022 – Elucid, Inc., a leading medical technology company providing physicians with AI-powered imaging analysis software to characterize cardiovascular disease, today announced the addition of Michael D. Lesh, MD, FACC, to its Board of Directors. “We look forward to what Dr. Lesh will bring to the board with his extensive background as a cardiologist, medtech ...
By Elucid
-
Creative Enzymes Launches Raw Materials for Manufacturing Diagnostic Kits
Creative Enzymes, a worldwide leading company in diagnostic enzymes manufacturing and supply, is committed to providing customers with diverse enzyme products and custom enzyme-related services for medical and research diagnosis. Recently, Creative Enzymes launched the raw materials for manufacturing Diagnostic Kits. The raw materials provided by Creative Enzymes include enzymes for cholesterol ...
-
BOC Sciences: Peptides Open New Path toward Osteoporosis Treatment
BOC Sciences declares that some of its peptide products have been proven applicable for osteoporosis treatment, which is a significant contribution to the therapeutic areas. Bone tissue engineering and the research surrounding peptides have expanded significantly over the last few decades. Several peptides have been shown to support and stimulate the bone healing response and have been proposed ...
By BOC Sciences
-
Prof. Krestin Joins Fluidda’S Board of Directors
INTRODUCTION Gabriel Krestin received his MD from the University of Cologne, Germany where he also specialized in radiology, in 1981 and his PhD (Habilitation) in 1989. From 1990–1997, he worked at the University Hospital in Zürich/CH, including a period as acting chairman of the Department of Radiology. In 1997 he moved to Erasmus MC in Rotterdam, Netherlands where he was the ...
By Fluidda
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you